During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
